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Abstract. N-(2-aminophenyl)-4-[N-(pyridine-3yl-methoxy-
carbonyl) aminomethyl] benzamide (MS-275) is a second
generation histone deacetylase (HDAC) inhibitor with signi-
ficant anti-tumor efficacy currently in clinical development.
We investigated the effect of MS-275 treatment on various
colon cancer cell lines, as well as on mouse xenograft models
derived from human colorectal cancer. MS-275 exerted
strong anti-proliferative effects in five cell lines and increased
the acetylation of histones 3 and 4. In vivo testing of the
compound in eight different models of human colon cancer
derived from primary colorectal cancers or from established
cell lines revealed that five models were responders, two
non-responders and one an anti-responder. Gene expression
profiles were determined in order to identify genes and
pathways differentially regulated upon MS-275 treatment in
responder versus non-responder models. Principle component
analysis revealed a correlation of the anti-tumor efficacy with
the sub-clustering of the MS-275 treatment groups in 7 out of
8 models. Although the overall gene expression pattern was
rather unique for each individual model, 129 genes were
significantly up- and 58 genes significantly down-regulated
in at least 2 out of 5 responder models in response to MS-275
treatment. We identified potential biomarkers for response to
MS-275, such as PRA1, MYADM and PALM2-AKAP2
which were up-regulated in all responder models and down-
regulated or unchanged in all non-responder models. Our
results provide a starting point for the development of clinically
relevant biomarkers for predicting a response to MS-275 and
the understanding of the mode of action of this HDAC
inhibitor.
Introduction
In recent years it has become clear that deregulation of
epigenetic processes plays a major role in tumorigenesis (1-5).
The term epigenetics relates to changes in gene expression
elicited by modifications of histone marks such as acetylation
or methylation as well as of DNA methylation, all of which
do not alter the DNA sequence (6-11). These modifications
may be transmitted over generations or be of more transient
nature.
Local modification of histone acetylation is an important
factor regulating the access of transcription factors to DNA
(5,7,10). This is controlled by histone acetyltransferases and
histone deacetylases (HDACs), and plays an important role
for normal cellular functions including regulation of cell
cycle progression, differentiation and apoptosis (12-14). The
abnormal activity of these key modulators of chromatin
structure may be associated with the development of a
malignant phenotype. Indeed, overexpression of HDACs as
well as aberrant recruitment to promoters leading to conden-
sation of chromatin and to silencing of tumor suppressor
genes has been reported in several cancer types (12-15).
The inhibition of HDAC activity results in the hyper-
acetylation of the tails of histone 3 (H3) and histone 4 (H4).
This facilitates the relaxation of the chromatin structure and
allows the re-expression of silenced genes, including p21
(16-21). In addition, several genes are repressed following
HDAC inhibition and, intriguingly, the number of down-
regulated genes may be as high as that of up-regulated ones
(22). Generally, pro-apoptotic and anti-proliferative genes
show increased expression after HDAC inhibitor treatment
whereas anti-apoptotic and pro-growth genes are down-
regulated (23-25). Furthermore, direct acetylation and regu-
lation of transcription factors such as p53, STAT1 or steroid
receptors leading to modifications in gene expression patterns
also account for some of the effects of HDAC inhibitors
(26,27). A third mechanism of action not directly linked to
gene regulation has been evidenced. It involves the direct
acetylation of non-transcriptional targets such as HSP90,
tubulin or Ku70 (26).
HDAC inhibitors represent a structurally diverse group of
compounds. Most, like suberoylanilide hydroxamic acid
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(SAHA) and trichostatin A (TSA) inhibit the activity of
many if not all HDACs (28-34). N-(2-aminophenyl)-4-[N-
(pyridine-3yl-methoxy-carbonyl) aminomethyl] benzamide
(MS-275) has a much more restricted profile (28,35-37).
Several studies indicate that MS-275 is a selective inhibitor of
HDAC1 and HDAC2, with IC50 values in the sub-micromolar
range (28,31,32). The compound shows significant anti-
tumor efficacy in vitro and in vivo and is currently in phase
I/II clinical trials (35).
In the current study, we investigated the efficacy of MS-
275 in human colon cancer models in vitro and in vivo. A
large number of colorectal cancers show, in addition to
genetic alterations such as p53 and ß-catenin mutations,
epigenetic abnormalities such as changes in DNA methylation
and in histone modification pattern (38). Also, overexpression
of HDAC2 has frequently been observed in colon cancers
(39). We first determined the effects of MS-275 on the proli-
feration of colon cancer cell lines and analyzed pharmacody-
namic markers. We then treated tumors grown as xenografts
from eight different human colon cancer models with MS-
275 and determined gene expression profiles. Since not all
models showed a significant tumor inhibition upon treatment,
the comparison of these expression profiles may represent
the basis to learn more about the mode of action of MS-275
and to find markers that may help to distinguish between
responders and non-responders to treatment.
Material and methods
Cell culture and reagents. Human colon carcinoma cell lines
Colo205, HCT116, HT29, LoVo and SW480 were purchased
from the American Type Culture Collection (Bethesda, MD,
USA) or the German Collection of Microorganisms and Cell
Cultures (Braunschweig, Germany) and cultured according to
the guidelines. For immunoblot analysis, cells were treated
with 0.3 or 3 μM MS-275 (Bayer Schering Pharma AG,
Berlin, Germany) for 24, 48 or 72 h. Cells were rinsed with
PBS and centrifuged at 1200 x g for 5 min. Total protein
extracts were prepared using the M-PER reagent (Perbio,
Bonn, Germany) and protein concentrations were determined
with the BCA-Assay (Perbio).
SDS-PAGE and immunoblotting. For SDS-polyacrylamide
gel electrophoresis (PAGE), total protein extracts were
prepared in sample buffer (4 x LDS sample buffer, 10 x
reducing agent), heated at 95˚C for 5 min and loaded onto
4-12% NuPAGE Bis-Tris gels. After electrophoresis, proteins
were transferred to polyvinylidene difluoride membranes
(all accessories and buffers for PAGE were purchased from
Invitrogen, San Diego, CA, USA) and blocked in 5% skimmed
milk in TBS containing 0.1% Tween-20 (TBST) for 30 min.
The following primary antibodies were diluted in 5% skimmed
milk in TBST: anti-p21 (1:200; Santa Cruz Biotechnology,
Santa Cruz, CA, USA); anti-acetylated histone 3 and histone 4
(1:2000 and 1:20000, respectively; Upstate, Chemicon,
Hampshire, UK); anti-HDAC2 (1:2000; Abcam, Cambridge,
UK); anti-GAPDH (1:5000; Zytomed Systems, Berlin,
Germany), and incubated overnight at 4˚C. Membranes were
washed three times with TBST and incubated with horse-
radish peroxidase-conjugated anti-mouse or anti-rabbit
antibodies (1:10000 in 5% skimmed milk in TBST, Dianova,
Hamburg, Germany) for 45 min at room temperature. Before
chemiluminescence detection (ECL plus, GE Healthcare,
Munich, Germany) membranes were washed three times
with TBST.
Proliferation assay. After trypsinization, cells were seeded in
96-well plates at 10,000-30,000 cells per well, depending on
growth properties, and allowed to adhere overnight. MS-275,
dissolved in DMSO and diluted in medium, was added at
different concentrations ranging from 0.001 to 10 μM. After
72 h the medium was replaced with 30% Alamar Blue
solution (diluted in medium; Invitrogen) and the cells were
incubated for 4 h at 37˚C (80% humidity, 95/5% air/CO2).
Inhibition of proliferation was detected colorimetrically by
measuring the excitation at 590 nm and plotting it against
MS-275 concentration. The IC50 values were calculated using
these graphs.
Gene expression knock-down experiments. For small
interfering RNA (siRNA) silencing of HDAC2, a predesigned
siRNA pool and the non-targeting siCONTROL siRNA pool
was used (Dharmacon, Perbio). HCT116 cells were seeded
at a concentration of 1000 cells per well in a 96-well plate
and transfected with 20 nM siRNA using the HiPerFect
transfection reagent (Qiagen, Hilden, Germany) according to
the manufacturer's guidelines. Twenty-four hours after trans-
fection, different concentrations of MS-275, ranging from
0.001 to 10 μM, were added to the cells. Proliferation was
assessed with the Alamar Blue assay after 72 h of MS-275
treatment. For validation of HDAC2 knock-down efficiency
and viability of the cells, 105 cells were seeded in a 24-well
plate and transfected with 20 nM siRNA. RNA and proteins
were isolated from the same well using the AllPrep RNA/
Protein Kit (Qiagen) according to the standard protocol.
HDAC2 knock-down efficiency was measured by quanti-
tative real-time polymerase chain reaction (PCR) and
immunoblotting.
Animal experiments. For tumor xenograft experiments, 6-week-
old female nude mice (NMRI-nu/nu) were utilized. HCT116
cells (1.5x106), HT29 cells (1x106) and LoVo cells (1.5x106)
were mixed with matrigel (BD Biosciences, Heidelberg,
Germany) and injected subcutaneously into one flank. Human
colon carcinoma tissue was obtained from primary tumors
(Co5854, Co5776 and Co5676) or liver metastases of colon
cancer (Co5841 and Co6044). Tumor fragments (2-3 mm3)
were transplanted onto the flanks of anaesthetized nude mice.
Primary xenograft models were established at the Max-
Delbrück-Center for Molecular Medicine, Berlin, Germany
(40). After the tumors became palpable, MS-275 treatment
was initiated. The mice received a daily oral dose of 0, 10 or
40 mg/kg MS-275. Irinotecan (Campto®, Pfizer, Karlsruhe,
Germany) was used as a positive control substance and given
intraperitoneally at a daily dose of 15 mg/kg. The diameter of
the tumors was measured twice weekly with a caliper and
tumor volumes were calculated by the formula: (width2 x
length) x 0.5. The median values of treated versus control
(T/C) values of the groups were used to evaluate the thera-
peutic efficacy.
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RNA extraction. Tumor tissue was taken from sacrificed
animals, snap-frozen and stored at -80˚C until use. Total
RNA was extracted using the RNeasy mini kit (Qiagen)
according to the manufacturer's recommendations including a
DNase I (Qiagen) step to digest genomic DNA. The quality
of total RNA was checked for integrity using the RNA
LabChips on the Agilent Bioanalyzer 2100 (Agilent Techno-
logies Inc., Palo Alto, CA, USA) and the concentration was
determined on a Nanodrop spectrophotometer (Peqlab,
Erlangen, Germany).
In vitro RNA transcription and hybridization to Affymetrix
GeneChips. The One-Cycle Eukaryotic Target Labeling Kit
(Affymetrix Inc., Santa Clara, CA, USA) was used according
to the manufacturer's instructions. Briefly, 2 μg of high
quality total RNA were reverse-transcribed using a T7 tagged
oligo-dT primer for the first-strand cDNA synthesis reaction.
After RNase H-mediated second-strand cDNA synthesis, the
double-stranded cDNA was purified and served as template
for the subsequent in vitro transcription reaction which
generates biotin-labeled complementary RNA (cRNA). The
biotinylated cRNA was then cleaned up, fragmented and
hybridized to GeneChip HGU133Plus2.0 expression arrays
(Affymetrix), which contain 54675 probe sets. The GeneChips
were washed and stained with streptavidin-phycoerythrin on
a GeneChip Fluidics Station 450 (Affymetrix). After washing,
the arrays were scanned on an Affymetrix Gene-Chip 3000
scanner with autoloader and barcode reader. A total of 169
HGU133Plus2.0 arrays were processed.
Data analysis. The quality of the hybridized arrays was
analyzed with the Expressionist Pro 4.0 Refiner software
(Genedata, Basel, CH). The following analyses were
performed, based on raw intensities of individual oligonu-
cleotide features (probes): the experiments were grouped
according to similarity and potential outlier experiments
were removed (or selected for re-hybridization and/or re-
fragmentation), the quality of a particular experiment was
compared with a virtual reference experiment, which was
computed as average of all feature intensities of all arrays in
that group. Moreover, defects on the arrays were masked.
Here, for each array, the spatial signal distribution was
compared with the reference experiment of the experiment
group it belonged to. Regions with sharp boundaries which
had consistently higher or lower feature intensities compared
to the reference experiment were flagged as defects and
excluded from further analysis. In addition, a signal correction
(distortion and gradient) was performed, the control gene
statistics were calculated, and an overall classification of the
quality of the experiments was provided.
The probe intensities on each array were summarized
with the MAS5.0 summarization algorithm and the refined
and summarized data were loaded into the CoBi database
(Genedata). The analysis of the probeset-specific signal
intensities was performed with the Expressionist Pro 4.0
Analyst software (Genedata). The data set was median
normalized. Pathway analyses were performed with the
GeneGo Metacore database and software tools.
Quantitative real-time RT-PCR. Aliquots of the total RNA
from all tumors belonging to one treatment group were
pooled and reverse-transcribed using the SuperScript III
First-Strand Synthesis System for RT-PCR (Invitrogen)
containing 3 μg RNA, 5 ng/μl random hexamer primer and
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Figure 1. Analysis of MS-275 pharmacodynamic markers in colon cancer cell lines. (A) Immunoblotting analysis of p21 expression, of H3 and H4
acetylation, and of HDAC1 and HDAC2 levels after MS-275 treatment for the indicated timepoints (in hours). GAPDH levels were determined as controls.
(B) Evaluation of HDAC2 protein down-regulation after siRNA treatment of HCT-116 cells for the indicated timepoints. (C) Impact of HDAC2 levels on the
anti-proliferative effects of MS-275 on HCT116 cells.
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1 mM deoxynucleotide triphosphate mix in a final volume of
20 μl. After an initial denaturation step at 65˚C for 5 min, the
reverse transcriptase reaction was carried out at 25˚C for
10 min, 50˚C for 50 min and 85˚C for 5 min. Real-time PCR
was carried out using predesigned TaqMan assays and TaqMan
Fast Universal Master mix on an Applied Biosystems 7500
Fast Real-Time PCR System (Applied Biosystems Applera
Deutschland GmbH, Darmstadt, Germany). Three genes
were selected for quantitative real-time PCR analysis: preny-
lated rab acceptor 1 (PRA1, assay ID Hs00197506), myeloid-
associated differentiation marker (MYADM, assay ID
Hs00414763_m1) and paralemmin 2-A kinase anchor protein
2 (PALM2-AKAP2, assay ID HS00364914_m1). The levels
of 18S rRNA transcripts (assay reference 4319413E) were
determined as control. The real-time PCR reaction was
performed in 96-well plates and contained 100 ng cDNA,
12.5 μl 2 x TaqMan Fast Universal Master mix, 1.25 μl
TaqMan Assay Mix and 1.25 μl 18S rRNA primers/probe
mix in a 25 μl reaction mix. After an initial denaturation step
at 95˚C for 20 sec, 40 cycles consisting of denaturation at
95˚C for 3 sec and annealing at 60˚C for 30 sec were carried
out. Triplicate values were determined for each sample.
The relative expression of each gene was determined on
the basis of the comparative threshold cycle method (ΔΔCT
method). A standard curve was generated with 18S rRNA in
every real-time PCR run. Each CT value was normalized
for the CT value of the 18S rRNA gene (ΔCT). Then, the
normalized gene expression value of the calibrator (i.e., ΔCT
of the vehicle control group) was subtracted from the norma-
lized target gene expression (i.e., ΔCT of the MS-275 treatment
groups) to obtain the ΔΔCT value and the fold change of the
gene in the treatment groups relative to the untreated control
tumors was calculated.
Results
In vitro efficacy of MS-275. We assessed the anti-
proliferative effects of MS-275 on the five established colon
cancer cell lines LoVo, HCT116, HT29, SW480 and Colo205
by determining cell numbers after a 3-day treatment. MS-275
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Figure 2. Experimental workflow for analysis of human colon cancer xenograft models. Eight different models were used for treatment with MS-275. The
mice (N=8 per treatment group) were given vehicle control, 10 or 40 mg/kg of MS-275. RNA from individual tumors was isolated, cRNA was synthesized
and hybridized to Affymetrix HGU133Plus2.0 arrays. The normalized dataset was subjected to unsupervised and supervised analyses with the Expressionist
Pro 4.0 Analyst software.
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inhibited all cell lines with IC50 values varying from 0.45 to
2.18 μM (Fig. 1A). The treatment led to arrest in the G0/G1
phase and apoptosis (data not shown). We then tested the
induction of the cyclin-dependent kinase inhibitor p21 which
is induced upon treatment by several HDAC inhibitors and
reflects the anti-proliferative effects of this compound class.
We found that at a sub-IC50 concentration (0.3 μM), MS-275
induced p21 expression in LoVo, HCT116 and SW480 cells,
whereas no such effect was detectable in HT29 and Colo205
cells (Fig. 1A). A 10-fold higher concentration of MS-275
induced p21 expression in Colo205, but not in HT29 cells
(not shown). We then examined changes in histone ace-
tylation. Stimulation of H3 acetylation was observed after
24-48 h in all cell lines, except in HT29 cells where it was
observed only after 72 h of treatment. The amount of ace-
tylated H3 was further increased when a higher MS-275
concentration (3 μM) was used. An increase in H4 hypera-
cetylation was observed in all cell lines after 24 h of MS-275
treatment, albeit to different extents.
HDAC1 and HDAC2 are the main targets of MS-275
(28,35-37). We therefore used immunoblotting to look at
their expression levels in the different colon cancer cell lines
(Fig. 1A). For HDAC1, very low basal levels were found. An
induction was initially observed upon MS-275 treatment in
HCT116, HT29 and Colo205 cells, followed by a decrease
after 72 h. LoVo and SW480 cells showed almost no expres-
sion of HDAC1. Thus, the HDAC1 protein levels did not
correlate with the anti-proliferative activity of MS-275.
Concerning HDAC2, we found that LoVo, HCT116 and
HT29 cells strongly expressed it. SW480 and Colo205 had
no detectable levels which were very slightly stimulated after
MS-275 treatment. Thus, a higher HDAC2 expression level
correlated with a high potency of MS-275.
In order to determine whether this finding had a functional
relevance for MS-275 efficacy, we performed RNAi knock-
down studies and subsequent proliferation assays in HCT116
cells. The HDAC2 mRNA level was dramatically reduced
after siRNA transfection (not shown) and HDAC2 protein
was no longer detectable, as assessed by immunoblotting
(Fig. 1B). The down-regulation of HDAC2 was specific, as
no reduction of HDAC1 mRNA or protein levels was seen
(not shown). HDAC2 knock-down reduced the efficacy of
MS-275 in proliferation assays. Only 20% growth inhibition
was observed 72 h after 1 μM MS-275 treatment in HCT-116
cells transfected with HDAC2-specific siRNAs compared to
more than 40% in the control transfected cells (Fig. 1C). The
respective IC50 values were 1.25 and 0.89 μM. Thus, knock-
down of HDAC2 partly abrogated the anti-proliferative effect
of MS-275, suggesting that this isoform was the relevant
molecular target.
In vivo efficacy of MS-275. In order to better evaluate the
therapeutic efficacy of MS-275 in colon cancer, different
primary tumor models (Co5854, Co5676 and Co5776), two
metastasis models (Co5841 and Co6044), as well as three
xenograft models derived from the cell lines that responded
best to MS-275 treatment (HCT116, HT29 and LoVo) were
tested (Fig. 2). Tumor-bearing mice were treated with 0, 10
or 40 mg/kg MS-275 once daily, and the tumor volumes were
measured twice weekly. The growth curves observed for
three tumors (Co5854, HT29 and Co5776) after MS-275
treatment are depicted, in comparison to irinotecan treatment
(Fig. 3). The anti-tumor efficacy of MS-275 given daily at a
40 mg/kg concentration to treat the different colon cancer
models is shown in Table I. The growth of 5 out of 8 models
was significantly inhibited, as the tumor volume ratio between
treated and control mice (T/C) was below 0.6 (i.e., 40%
tumor growth inhibition). Two models were classified as
non-responders with T/C values of 0.7 and 1.22 (Co5841 and
Co5776, respectively). The LoVo model grew faster than the
control following MS-275 treatment (T/C value of 2.04)
leading to its classification as an anti-responder. Thus, this
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Figure 3. Efficacy of MS-275 on tumor growth in the responder models
Co5854 and HT29, and in the non-responder model Co5776. Tumor volume
was determined at the indicated timepoints. Irinotecan treatment was used as
comparison.
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Figure 4. Analysis of pharmacodynamic markers in vivo. Tumors were treated with 40 mg/kg MS-275 and analyzed by immunoblotting for their levels of
HDAC2, p21 and acetylated H3 at the end of the study. GAPDH levels were determined as controls.
Figure 5. PCA of all models and correlation between MS-275 efficacy and clustering. (A) PCA clustering of all models. (B) PCA of each individual model
indicates sub-clustering for treatment groups and correlation to response to MS-275 for responder and anti-responder models. The box plots show the tumor
volume at the end of the experiment. The asterisk indicates a statistically significant change in tumor volume of treated animals compared to untreated ones
(p<0.05).
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study revealed that some models were responders and others
non-responders or even anti-responders to MS-275 treatment.
Immunoblotting experiments were then performed to
determine the effects of MS-275 on HDAC2 and p21 protein
levels, and on H3 acetylation (Fig. 4). HDAC2 expression
was detected in most untreated tumors (with the exception
of Co5854) and in all treated tumors. Both up- and down-
regulation were observed following MS-275 treatment.
Concerning p21, strong re-expression was seen only in treated
LoVo and HCT116 cells tumors. Hardly any signal was
detected in the other tumor models. The induction of p21 did
not correlate with the response to MS-275 as LoVo was an
anti-responder and HCT116 a responder model. Concerning
H3 acetylation, an increase was observed in most cases after
MS-275 treatment, with the exception of Co5854 and Co6044.
Gene expression profiling - unsupervised analysis. RNA
isolated from the xenograft models was subjected to global
gene expression profiling in order to identify genes that were
regulated by MS-275 and genes selectively regulated in
responder versus non-responder tumor models (Fig. 2). Total
RNA from each individual tumor was isolated, the corres-
ponding cRNA synthesized and hybridized to a total of 169
Affymetrix HGU133Plus2.0 GeneChips. After median norma-
lization the individual arrays were subjected to principle
component analysis (PCA) to remove outliers at the expression
level. Co-clustering of samples derived from each established
cell line or from each colorectal cancer was visible, regardless
whether the mice were treated with MS-275 or not (Fig. 5A).
The three primary tumor responder models Co5841, Co5676
and Co6044 showed similar gene expression patterns in the
PCA and differed from the two primary non-responder
models Co5841 and Co5776. Consequently, among primary
tumors, the PCA distinguished between responders and non-
responders (Fig. 5A). Altogether these results indicate that
the overall gene expression patterns differed more among the
models than did the expression changes induced by MS-275
treatment for each individual model.
Next, we asked whether response to MS-275 correlated
with a sub-clustering of treatment groups and therefore
performed PCA on each individual model (Fig. 5B). For all
responder models, we observed a sub-clustering that
distinguished the non-treated from the two MS-275-treated
tumor groups at the gene expression level. Conversely, such
a clustering was not observed in the two primary tumor
models that did not respond to MS-275. The situation was
different for the anti-responder model LoVo for which a
dose-dependent increase in tumor growth was seen. Here,
sub-clustering of the non-treated and of each treated group
was observed.
Gene expression profiling - supervised analysis. Next,
supervised analyses were performed to determine if MS-275
treatment led to uniform alterations of gene expression
patterns. The following comparisons were performed for
each model: 10 mg MS-275 versus control, 40 mg MS-275
versus control, 10 and 40 mg MS-275 versus control, and 10
versus 40 mg MS-275. For statistical analyses, we chose a
Welch-test and selected regulated genes with a fold change >5
and a p-value <10-4. In addition, analysis of variation
(ANOVA; p<10-5) and K-ordered groups tests (p<10-2) were
carried out. The most significantly regulated genes in presence
of 40 mg/kg MS-275 as identified with all three statistical
tests are listed in Table II. This analysis showed that genes
were regulated more significantly in cell line models than in
primary models. Also, more genes were up- than down-
regulated in responder models whereas in non-responder
models, most genes were down-regulated. When looking at
the most significantly regulated genes in each individual
model, we observed rather heterogeneous changes. The
responder models HT29 and Co5854 showed a strong up-
regulation of genes involved in cell adhesion and cell-cell
communication [for instance LGALS1 (18.8-fold) and
NRCAM (90-fold)], whereas the non-responder models
Co5776 and Co5841 showed a down-regulation of genes
involved in cell adhesion [CLDN4 (1.6-fold) and TSPAN5
(2-fold)]. In HT29 cells, CEACAM6 and CEACAM7 were
up-regulated 4- and 17.7-fold, respectively. MS-275 treatment
of the HCT116 and Co5676 models led to down-regulation
of cell cycle-promoting genes like TNFSF4 (20-fold), BTC
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Table I. In vivo anti-tumor efficacy of MS-275 in experimental human colon carcinoma models.a
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Model Origin Duration of Median volume of Median volume of T/C Classification
experiment control tumors MS-275 treated
(days) (cm3) tumors (cm3)
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
HT29 Cell line 26 0.51 0.09 0.18 Responder
HCT116 Cell line 21 0.48 0.26 0.54 Responder
LoVo Cell line 58 0.27 0.55 2.04 Anti-responder
Co5676 Tumor 49 1.35 0.12 0.09 Responder
Co5776 Tumor 50 1.90 2.31 1.22 Non-responder
Co5841b Tumor 46 1.08 0.76 0.70 Non-responder
Co5854 Tumor 27 1.91 0.82 0.43 Responder
Co6044b Tumor 29 2.07 0.50 0.24 Responder
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
aTumor models were transplanted into nude mice and treated daily with 40 mg/kg MS-275. bTumors originating from secondary liver
metastatic deposits.
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
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(4.4-fold) and KPNA2 (1.9-fold). In the non- and anti-
responder models Co5776, Co5841 and LoVo, genes involved
in the regulation of transcription were up-regulated [NSBP1
(12.2-fold), GTF2H1 (1.4-fold) and EZH2 (1.4-fold)] or
down-regulated [FOXL1 (5-fold) and GLIS3 (3.1-fold)].
Interestingly, gelsolin (GSN) was down-regulated 4.8-fold in
the Co5841 model.
As we did not observe a strong overlap of regulated genes
between the five responder models, we used less stringent
criteria. We called for a significant change in the expression
level in at least two of the three statistical tests. With this new
setting we identified 116 up- and 43 down-regulated genes
after MS-275 treatment that exhibited a dose-dependent
regulation in at least 4 out of 5 responder models. Interestingly,
34 of these genes showed up-regulation in all responders and
down-regulation or no change of regulation in at least 2 out
of 3 non-responders, whereas 13 genes exhibited down-
regulation in all responders and up-regulation or no change in
at least two out of three non-responders (Table III). These
genes may serve as biomarkers to predict the response to
MS-275.
Confirmation of microarray data by quantitative real-time
RT-PCR. The three most significantly regulated genes showing
up-regulation in most responder models but not in non-
responder models were those coding for PRA1, MYADM
and PALM2-AKAP2 (Fig. 6A). Quantitative real-time PCR
was performed to confirm these findings. Total RNA was
extracted from each treatment group for each model. The
normalized gene expression levels in treated tumors relative
to the expression in untreated tumors are shown in Fig. 6B.
The quantitative real-time PCR analysis confirmed the up-
regulation of these three genes in at least four of the five
responder models and the down-regulation or no change in
at least 2 of the 3 non-responder models. However, in the
LoVo model, the absence of up-regulation of PRA1 and
MYADM could not been confirmed by quantitative real-time
RT-PCR.
Pathway analysis. To gain a deeper insight into the
mechanisms of action of MS-275, we performed a pathway
analysis using the GeneGo Metacore database and software
(Fig. 7). Genes regulated by MS-275 treatment as compared
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Table II. Most significantly regulated genes in colon carcinoma xenograft models in response to 40 mg/kg MS-275.a
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Up-regulated Down-regulated
––––––––––––––––––––––––––––––––––––––––––––– ––––––––––––––––––––––––––––––––––––––––––––––––
Model Gene symbol Probeset ID Fold change Gene symbol Probeset ID Fold change
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
HT29 LGALS1 201105_at 18.83 AKAP7 205771_s_at 0.05
CEACAM7 206199_at 17.66 LGALS2 208450_at 0.10
PTPRO 208121_s_at 16.30 MUC5AC 214385_s_at 0.17
HCT116 FAM49A 209683_at 34.51 TNFSF4 207426_s_at 0.05
NGFRAP1L1 229963_at 18.44 KLRC1 206785_s_at 0.10
FLJ35767 241367_at 10.32 KLRC3 207723_s_at 0.13
Co 5676 HLA-DQB1 212998_x_at 13.20 PAPSS2 203058_s_at 0.43
RNF182 230720_at 8.14 KPNA2 211762_s_at 0.53
BAMBI 203304_at 6.23 HIGD1A 221896_s_at 0.53
Co 5854 NRCAM 204105_s_at 89.52 AQP3 39248_at 0.26
TNNT1 213201_s_at 35.30 MATN2 202350_s_at 0.30
SCG5 203889_at 20.01 ST6GALNAC1 227725_at 0.35
Co 6044 TNNT1 213201_s_at 21.59 TCN1 205513_at 0.08
TUBB2B 214023_x_at 14.25 KRT6B 213680_at 0.17
NES 218678_at 9.25 CDKN1C 213348_at 0.20
LoVo NES 218678_at 13.16 FOXL1 243409_at 0.20
NSBP1 221606_s_at 12.20 MLPH 218211_s_at 0.20
SCNN1A 203453_at 11.98 HHIP 237466_s_at 0.21
Co 5776 NUPL1 204435_at 1.58 SLC16A1 1557918_s_at 0.24
RAP1GDS1 209444_at 1.52 P4HB 200654_at 0.57
ORC4L 203351_s_at 1.51 CLDN4 201428_at 0.64
Co 5841 PSMB4 228204_at 1.78 GSN 214040_s_at 0.21
DSG3 235075_at 1.55 RNF144 204040_at 0.47
IQGAP3 229538_s_at 1.52 NETO2 218888_s_at 0.48
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
aGenes were selected by the overlap of three different statistical tests [Welch-test (p<10-4), ANOVA (p<10-5) and K-ordered groups (p<10-2)],
respectively.
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
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Figure 6. Examples of genes regulated upon MS-275 treatment. Genes were selected by the overlap of 2 out of 3 statistical tests [Welch-test (p<10-4),
ANOVA (p<10-5) and K-ordered groups tests (p<10-2)]. (A) Normalized expression of three selected genes showing an up-regulation in responder but not in
non-responder or anti-responder models. Normalized expression levels for control (white columns), 10 mg/kg MS-275 (light grey columns) and 40 mg/kg
MS-275 (dark grey columns) are shown. (B) Confirmation of expression changes of selected genes by quantitative real-time PCR of pooled RNA from each
tumor and treatment group. Fold changes normalized to vehicle control are shown in light grey columns (10 mg/kg MS-275) and dark grey columns (40 mg/kg
MS-275). Mean values ± SD of three independent real-time PCR runs are shown.
Figure 7. The pathways most significantly regulated after MS-275 treatment (40 mg/kg) were categorized using the GeneGO Metacore database according to
their involvement in cellular processes. One pathway can be a member of more than one process.
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to the corresponding control groups were submitted to path-
way analysis. Affected pathways were sorted according to
the total number of affected genes and the significance of the
regulation (p-value). The 100 most significantly regulated
pathways were categorized according to the cellular processes
they affected (p<0.017). This revealed that the most perturbed
cellular processes following MS-275 treatment were cell
adhesion, response to extracellular stimuli and transcription.
Discussion
This study was devised to examine the anti-tumor effects of
MS-275 in in vitro and in vivo models of human colorectal
cancer. MS-275 is a potent HDAC inhibitor with selectivity
for the class I family members (28,35-37). Treatment of five
colon cancer cell lines with MS-275 at a sub IC50 concentration
revealed that efficacy did not correlate with changes in
previously described pharmacodynamic markers such as p21
expression or H3 and H4 acetylation. However, the expression
of HDAC2 in the cell lines correlated best with MS-275
efficacy in vitro. In line with this, HDAC2 knock-down
resulted in a partial abrogation of the anti-proliferative potency
of the compound. These results are consistent with previously
published ones reporting that loss of HDAC2 expression and
activity in sporadic cancers rendered them resistant to the
HDAC inhibitor TSA (41). Transfection of wild-type HDAC2
into the HDAC2-deficient colon cell line RKO restored
TSA sensitivity (41). We found that the five colon cancer
cell lines, as well as the eight xenograft models expressed
full-length HDAC2. This isoform is therefore likely to be
responsible for at least some of the anti-proliferative effects
we observed. On the other hand, the fact that nearly complete
elimination of HDAC2 did not entirely obliterate the anti-
proliferative effect of the compound strongly suggests that
additional cellular targets might be involved in the anti-tumor
effects of MS-275.
Predicting the efficacy of MS-275 in vitro can therefore
not solely be based upon examination of a single marker.
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Table III. Oppositely regulated genes in responder and non-responder models following treatment with 40 mg/kg MS-275.a
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
A, Log2 ratio vehicle control versus 40 mg/kg MS-275
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Responders Non-responders Down or
––––––––––––––––––––––––––––––––––––––––––– ––––––––––––––––––––––––– Up in no change in
Gene symbol Probeset ID HT29 HCT116 Co5676 Co5854 Co6044 LoVo Co5776 Co5841 responders non-responders
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
PALM2-
AKAP2 202760_s_at 2.4 2.5 1.6 3.4 1.9 0.8 0.8 0.7 5/5 3/3
PRA1 203136_at 2.7 2.4 1.7 1.3 2.3 0.9 0.8 0.9 5/5 3/3
OAT 201599_at 1.3 1.4 1.2 1.2 2.6 0.9 1.0 0.8 5/5 3/3
PRSS23 202458_at 1.0 2.4 2.0 1.6 1.3 0.4 0.8 0.8 5/5 3/3
C20orf3 206656_s_at 1.4 1.8 1.5 1.3 1.3 0.9 0.9 1.0 5/5 3/3
MYADM 225673_at 1.9 1.8 3.2 3.3 2.0 0.7 1.0 1.0 5/5 3/3
SH3KBP1 223082_at 1.8 1.2 1.6 1.1 1.5 0.8 0.9 1.0 5/5 3/3
DKFZP
564O0823 225809_at 3.4 2.3 1.7 1.9 2.1 1.4 0.7 0.9 5/5 2/3
LITAF 200706_s_at 1.5 1.9 1.4 1.3 1.6 1.1 0.9 0.9 5/5 2/3
NSMCE1 224666_at 1.4 1.1 1.2 1.6 1.7 0.9 1.1 1.0 5/5 2/3
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
B, Log2 ratio vehicle control versus 40 mg/kg MS-275
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Responders Non-responders Up or
––––––––––––––––––––––––––––––––––––––––––– –––––––––––––––––––––––– Down in no change in
Gene symbol Probeset ID HT29 HCT116 Co5676 Co5854 Co6044 LoVo Co5776 Co5841 responders non-responders
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
BAZ1A 217986_s_at 0.6 0.6 0.8 0.9 1.0 1.2 1.1 1.1 5/5 3/3
LACTB2 222714_s_at 0.5 0.9 0.5 0.8 0.6 1.8 1.0 1.0 5/5 3/3
FLJ21345 fis 234219_at 0.7 0.9 0.4 1.0 0.4 1.5 1.0 1.0 5/5 3/3
BID 211725_s_at 0.6 0.8 0.6 0.6 0.6 0.8 1.1 1.1 5/5 2/3
C6orf51 225083_at 0.5 0.4 0.8 0.6 0.5 0.9 1.2 1.0 5/5 2/3
HMGN2 208668_x_at 0.8 0.6 0.6 0.8 0.9 0.9 1.1 1.1 5/5 2/3
HSPC268 226780_s_at 0.6 0.6 0.5 0.5 0.7 0.9 1.0 1.1 5/5 2/3
LOC644246 230388_s_at 0.5 0.9 0.7 0.7 0.6 0.8 1.2 1.2 5/5 2/3
ADI1 217761_at 0.4 0.5 0.6 0.6 0.7 0.4 1.0 1.2 5/5 2/3
TRMT5 221952_x_at 0.7 0.5 0.5 0.8 0.8 0.9 1.1 1.1 5/5 2/3
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
aThe genes most significantly up-regulated in responder models and down- or not regulated in non-responder models are shown in (A). The genes most significantly down-regulated
in responder models and up- or not regulated in non-responder models are shown in (B). The ratio refers to the comparison of the 40 mg/kg and the vehicle control group. Genes
were selected by the overlap of two of three different statistical tests (either Welch-test, p<10-4 or ANOVA, p<10-5 and K-ordered groups, p<10-2).
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
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Only the combined examination of the above-mentioned
markers, and probably of even more, will allow the prediction
of the efficacy of MS-275. Strong p21 induction as well as
HDAC2 expression combined with strong and early H3 and
H4 hyperacetylation, as seen in HCT116 cells, correlated with
good response. The same holds true for the interpretation of
these markers in vivo. We did not observe that HDAC inhi-
bition led to H3 and H4 hyperacetylation and p21 induction of
expression, the claimed hallmarks of HDAC inhibition, in all
tested in vivo models of colon cancer. These changes can
thus not be ascribed to every model of human cancer and every
HDAC inhibitor. Our systematic analysis of different xenograft
models as well as the in vitro analysis of five different colon
cancer cell lines showed that there was a need for new, more
sensitive and reliable biomarkers to predict the response and
sensitivity of tumors to the treatment with MS-275.
We therefore performed microarray analyses of eight colon
cancer xenograft models to learn more about the mode of
action of MS-275 and to find markers that may help to distin-
guish between MS-275 responders and non-responders. The
present study revealed a rather non-uniform response towards
MS-275 treatment, which reflected the molecular heterogeneity
of the xenograft models used. We did not see a correlation
between the different types of xenograft models, either derived
from established cell lines or colorectal cancer, and the res-
ponse towards MS-275. We identified two responder cell lines
(HT29 and HCT116) and one anti-responder (LoVo), two
responder primary models (Co5854 and Co5676) and one non-
responder (Co5776), as well as one metastasis model responder
(Co6044) and one non-responder (Co5841). The gene expres-
sion profiles of these models were rather heterogeneous and
the PCA revealed more differences among individual models
than among treatment groups.
With the help of stringent statistical tests, we identified a
number of potential biomarkers for MS-275. These markers
were up-regulated dose-dependently upon MS-275 treatment
in the five responder models and showed no induction in the
three non-responder models. PRA1 is a ubiquitous protein
which binds to prenylated Rab GTPases (42). Its overexpres-
sion impairs TCF/ß-catenin signaling, which plays a prominent
role in colon cancer, possibly by limiting nuclear translocation
of ß-catenin (43). This was linked to ERK1/2 dephosphory-
lation. Re-expression of PRA1 upon MS-275 treatment may
therefore lead to inhibition of the TCF/ß-catenin pathway by
blockade of the nuclear translocation and thus prevention of
the transcriptional stimulation of genes involved in tumor
formation and proliferation. MYADM is associated with the
differentiation of hematopoietic and acute promyeolocytic
leukemia cells (44,45). All-trans retinoic acid treatment induces
expression of this differentiation marker in NB4 cells. The
up-regulation of this gene upon MS-275 treatment may reflect
the potential of the compound to induce differentiation in
tumor cells and could serve as a differentiation and response
biomarker for MS-275. Little is known about PALM2-AKAP2
(46). The corresponding mRNA is a naturally occurring cotran-
scribed product of the adjacent PALM2 and AKAP2 genes but
the significance of this co-transcribed mRNA and the function
of its putative protein product have not yet been determined.
A comparison of expression profiles of different HDAC
inhibitors revealed a very small overlap of regulated genes,
pointing out the importance of specific studies for each
HDAC inhibitor when it comes to evaluating and validating
stratification biomarkers. We studied the effects of MS-275
in eight different systems and found the overlap between
regulated genes to be rather small, suggesting that each model
carried individual patterns of epigenetic marks that contribute
to their differential gene expression and response to treatment.
Pathway analysis revealed that MS-275 strongly affected
cell adhesion pathways. Among the 100 most significantly
affected pathways, 20 were involved in the regulation of cell-
cell adhesion, communication, motility, or tumor invasion.
Several cell adhesion genes were up-regulated in MS-275
responder models but down-regulated in non-responder
models. In the HT29 and HCT116 models many integrins
and tetraspanins, such as ß1-integrin, CD9 or CD81, were
up-regulated, whereas these genes were down-regulated in
Co5841, Co5776 and LoVo. Besides that, E-cadherin, an
important suppressor of epithelial tumor cell invasiveness
and metastasis which is epigenetically silenced through
promoter methylation in many carcinomas (47), was down-
regulated in the non-responder models Co5841 and Co5776
upon MS-275 treatment. This implies that MS-275 did not
induce the re-expression of E-cadherin, but rather promoted
the hypermethylated status of the primary non-responder
models. E-Cadherin as well as claudin 4 (CLDN4), which
were down-regulated in Co5776, are decreased in diffuse
type and poorly differentiated tumors (47,48). Dysfunction of
these proteins may therefore play a role in disruption of cell-
cell adhesion. In conclusion, MS-275 might increase the
adhesive properties of tumor cells in responder models thus
preventing the metastatic spread and the immune escape of
the malignant cells, whereas in non-responder models most
cell adhesion molecules were down-regulated.
Taken together, the different in vitro and in vivo effects
of MS-275 as well as the expression changes induced in
responder and non-responder models revealed the pleiotropic
effects of this compound on different cellular pathways
affecting tumors and their microenvironment.
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